当前位置: X-MOL 学术Cell Death Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Salt-inducible kinase 1 regulates bone anabolism via the CRTC1-CREB-Id1 axis.
Cell Death & Disease ( IF 8.1 ) Pub Date : 2019-10-31 , DOI: 10.1038/s41419-019-1915-4
Min Kyung Kim 1 , Jun-Oh Kwon 1 , Min-Kyoung Song 1 , Bongjun Kim 1 , Haemin Kim 2 , Zang Hee Lee 1 , Seung-Hoi Koo 3 , Hong-Hee Kim 1
Affiliation  

New bone anabolic agents for the effective treatment of bone metabolic diseases like osteoporosis are of high clinical demand. In the present study, we reveal the function of salt-inducible kinase 1 (SIK1) in regulating osteoblast differentiation. Gene knockdown of SIK1 but not of SIK2 or SIK3 expression in primary preosteoblasts increased osteoblast differentiation and bone matrix mineralization. SIK1 also regulated the proliferation of osteoblastic precursor cells in osteogenesis. This negative control of osteoblasts required the catalytic activity of SIK1. SIK1 phosphorylated CREB regulated transcription coactivator 1 (CRTC1), preventing CRTC1 from enhancing CREB transcriptional activity for the expression of osteogenic genes like Id1. Furthermore, SIK1 knockout (KO) mice had higher bone mass, osteoblast number, and bone formation rate versus littermate wild-type (WT) mice. Preosteoblasts from SIK1 KO mice showed more osteoblastogenic potential than did WT cells, whereas osteoclast generation among KO and WT precursors was indifferent. In addition, bone morphogenic protein 2 (BMP2) suppressed both SIK1 expression as well as SIK1 activity by protein kinase A (PKA)-dependent mechanisms to stimulate osteogenesis. Taken together, our results indicate that SIK1 is a key negative regulator of preosteoblast proliferation and osteoblast differentiation and that the repression of SIK1 is crucial for BMP2 signaling for osteogenesis. Therefore, we propose SIK1 to be a useful therapeutic target for the development of bone anabolic strategies.

中文翻译:

盐诱导性激酶1通过CRTC1-CREB-Id1轴调节骨合成代谢。

有效治疗诸如骨质疏松症等骨代谢疾病的新型骨合成代谢剂具有很高的临床需求。在本研究中,我们揭示了盐诱导激酶1(SIK1)在调节成骨细胞分化中的功能。原代成骨细胞中SIK1的基因敲低,但SIK2或SIK3的表达没有,增加了成骨细胞的分化和骨基质矿化。SIK1还调节成骨过程中成骨细胞前体细胞的增殖。成骨细胞的这种阴性对照需要SIK1的催化活性。SIK1磷酸化CREB调控的转录共激活因子1(CRTC1),阻止CRTC1增强CREB转录活性以表达成骨基因,如Id1。此外,SIK1基因敲除(KO)小鼠的骨量,成骨细胞数更高,和同窝野生型(WT)小鼠的骨形成率。与WT细胞相比,来自SIK1 KO小鼠的成骨细胞显示出更多的成骨细胞潜力,而KO和WT前体之间的破骨细胞生成无差异。此外,骨形态发生蛋白2(BMP2)通过蛋白激酶A(PKA)依赖性机制抑制SIK1表达和SIK1活性,从而刺激成骨作用。两者合计,我们的结果表明SIK1是成骨细胞增殖和成骨细胞分化的关键负调控因素,而SIK1的抑制对于BMP2信号向成骨至关重要。因此,我们建议SIK1是骨合成代谢策略发展的有用的治疗目标。而在KO和WT前体中破骨细胞的产生是无关紧要的。此外,骨形态发生蛋白2(BMP2)通过蛋白激酶A(PKA)依赖性机制抑制SIK1表达和SIK1活性,从而刺激成骨作用。两者合计,我们的结果表明SIK1是成骨细胞增殖和成骨细胞分化的关键负调控因素,而SIK1的抑制对于BMP2信号向成骨至关重要。因此,我们建议SIK1是骨合成代谢策略发展的有用的治疗目标。而在KO和WT前体中破骨细胞的产生是无关紧要的。另外,骨形态发生蛋白2(BMP2)通过蛋白激酶A(PKA)依赖性机制抑制SIK1表达和SIK1活性,从而刺激成骨作用。两者合计,我们的结果表明SIK1是成骨细胞增殖和成骨细胞分化的关键负调控因素,而SIK1的抑制对于BMP2信号向成骨至关重要。因此,我们建议SIK1是骨合成代谢策略发展的有用的治疗目标。我们的结果表明,SIK1是成骨细胞增殖和成骨细胞分化的关键负调节剂,而SIK1的抑制对于BMP2信号向成骨的作用至关重要。因此,我们建议SIK1是骨合成代谢策略发展的有用的治疗目标。我们的结果表明,SIK1是成骨细胞增殖和成骨细胞分化的关键负调节剂,而SIK1的抑制对于BMP2信号向成骨的作用至关重要。因此,我们建议SIK1是骨合成代谢策略发展的有用的治疗目标。
更新日期:2019-11-01
down
wechat
bug